The biochemical and neurologic basis for the treatment of male erectile dysfunction

Journal of Pharmacology and Experimental Therapeutics

Volumn 296, Issue 2, 2001, Pages 225-234

  Moreland, Robert B ^a   Hsieh, Gin ^a   Nakane, Masaki ^a   Brioni, Jorge D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CORPUS CAVERNOSUM; DRUG MECHANISM; DRUG TARGETING; ERECTILE DYSFUNCTION; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; REVIEW; SMOOTH MUSCLE RELAXATION;

HUMANS; IMPOTENCE; MALE; NERVOUS SYSTEM; PENILE ERECTION;

EID: 0035146639     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat
2. Physiology of erection
3. Neuromodulation of penile erection: An overview of the role of neurotransmitters and neuropeptides
4. A review of central 5-HT receptors and their function
5. Pharmacological analysis of male rat sexual behavior
6. Role of GABA during the multiple consolidation of memory
7. Oxytocin and sexual behavior
8. Dopaminergic neurotransmission at the paraventricular nucleus of hypothalamus in central regulation of penile erection in the rat
9. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease
10. Evaluation of oral RO 70-0004/003, an alpha 1A adrenoceptor antagonist in the treatment of male erectile dysfunction
11. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function
12. Cyclic GMP phosphodiesterase-5: Target of sildenafil
13. Neural control of penile erection
14. Neuropeptides and male sexual behavior
15. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study
16. Animal models used in erectile dysfunction
17. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group
18. Erectile function in cyclic GMP-dependent kinase I-deficient mice
19. Mechanisms of smooth muscle contraction
20. The effects of nicorandil on corpus cavernosal smooth muscle tone are mediated by potassium channel opening and guanylate cyclase stimulation
21. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts male aging study
22. Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection
23. An analysis of certain effects of bilateral temporal lobectomy in the rhesus monkey, with special reference to "psychic blindness"
24. Sexual dysfunction in the United States. Prevalence and predictors
25. Central control of penile erection
26. The influence of medication on erectile function
27. Dopamine and sexual behavior
28. The epidemiology and pathophysiology of erectile dysfunction
29. Oral and topical treatment of erectile dysfunction: Present and future
30. Is there a role of hypoxemia in penile fibrosis?
31. Prospectives in pharmacotherapy of male erectile dysfunction
32. Prostanoid receptors: Structures, properties and function
33. Impotence
34. Pharmacotherapeutic advances in the treatment of erectile dysfunction
35. Neurology of sexual behavior
36. Central effects of sildenafil on intracavernous pressure (ICP) following electrical stimulation of the MPOA
37. Intracavernosal therapy
38. Signal transduction in cavernous smooth muscle
39. Alpha adrenergic receptors in the penis
40. Pontine regulation of pelvic viscera: Pharmacological target for pelvic visceral dysfunction
41. Structure and function of dopamine receptors
42. Oxytocinergic innervation of autonomic nuclei controlling penile erection in the rat
43. Orally active agents: The potential of alpha-adrenoceptor antagonists